Safety and Pharmacokinetics of Cemiplimab Anti-programmed Death-ligand 1 (Anti-PD-1) and Other Agents in Japanese Adult Patients With Advanced Malignancies

Study Summary

Part 2 Cohorts A and C This study is being conducted to test the safety and pharmacokinetics of cemiplimab in patients with lung cancer. The study is also being conducted to test if cemiplimab, alone or in combination, can reduce the size of your tumor by helping the immune system destroy the tumor. Part 2 Cohorts D and E This study is being conducted to test the safety and pharmacokinetics of fianlimab and cemiplimab in patients with lung cancer. The study is also being conducted to test if fianlimab and cemiplimab, with or without chemotherapy, can reduce the size of your tumor by helping the immune system destroy the tumor.

Conditions

Advanced Malignancies

Interventions / Drugs

Cemiplimab Ipilimumab Platinum-doublet chemotherapy Gemcitabine Pemetrexed Paclitaxel Fianlimab

View on ClinicalTrials.gov ↗

Sponsor

REGN

Regeneron Pharmaceuticals

Antibody Therapeutics

F34/100

Study Details

Enrollment146 participants

Primary Completion—

Lead SponsorRegeneron Pharmaceuticals

Data Retrieved2026-04-11 02:55:54.866028+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.